When (if ever) would you re-challenge with immunotherapy for patients with metastatic RCC?
How are you incorporating CONTACT-03 data presented at #ASCO2023 into your practice? Would you consider immunotherapy re-challenge for someone on adjuvant pembrolizumab? What about for someone who's last immunotherapy exposure was >1 year ago?